preview delay demand fair valu
page full analyst note apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
aim transform human health practic
leadership genom sequenc firm provid broad rang
instrument relat consum help research
clinician identifi understand genet variat scale
project wide popul genom initi
pursu mani countri narrow non-invasive
prenat screen believ continu benefit
rapidli expand applic genom sequenc
tool innov select acquisit
past decad technolog advanc
sequenc industri larg led brought
cost assembl one genom nearli billion
human genom project complet
introduc highseq earli
innov like recent launch novaseq continu push
cost expect novaseq eventu
enabl genom could greatli increas
access genom sequenc lower cost genom
sequenc could wide appeal clinic diagnost
applic especi oncolog reproduct health
technolog perspect beat current
competit nearli everi measur -- run cost
turnaround time read length throughput error rate --
expect domin continu mani year threat
exampl think new sequenc techniqu includ nanopor
sequenc hold promis howev given difficulti
commerci new sequenc tool especi compar
test larg instal system base remain
unconvinc emerg system dethron
near futur meantim continu pursu
intern innov exist new sequenc method
although regulatori bodi may throw roadblock potenti
acquisit expect remain activ buyer new
technolog field possibl
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
provid tool servic analyz genet materi life
scienc clinic lab applic compani gener revenu
sequenc tool dedic consum sale illumina
high-throughput technolog enabl whole genom sequenc human
larg organ lower throughput tool enabl applic
requir smaller data output viral cancer tumor screen
also sell microarray sale enabl lower-cost
focus genet screen primarili consum agricultur
applic servic account sale includ basic
mainten servic clinic lab applic non-invasive
prenat oncolog rare-diseas screen whole genom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
preview delay demand fair
reveal top-lin result pull guidanc
mid-april narrow-moat announc full oper
result beat initi first-quart guidanc unfortun
like mani life scienc compani start
run challeng shelter-in-plac order
implement mid-march manag tone
second quarter remain cautiou cut
project significantli chang
fair valu estim view situat primarili
delay demand
first quarter gener million sale
high end guidanc rang million-
million compani also outperform bottom
line turn adjust ep previou
guidanc per share manag note
sale fell significantli end march though
custom restrict access close facil
gener sequenc sale remain robust array
sale consum servic remain
robust instrument sale term end user pattern
research run volum declin quickli mid-march
sinc remain roughli research
volum fourth quarter clinic volum
experienc gentler longer declin
run roughli volum fourth quarter
uncertainti around long volum remain
depress level remain mum
guidanc demand second quarter even
rest year may mute
cut project significantli
includ mid-single-digit sale mid-teen ep
declin howev expect demand
industry-lead sequenc tool rise substanti
crisi abat chang
fair valu estim delay demand
fair valu estim remain per share
valu firm around time expect
expect grow revenu
compound annual thank healthi demand
sequenc technolog project assum on-going
strength research applic well grow
adopt sequenc
custom still anticip research budget
continu priorit genom sequenc spend due
research advanc technolog provid
clinic diagnost market remain larg opportun
sinc sequenc potenti disrupt
segment older diagnost test addit creat
prenat screen repres near-term clinic growth
opportun ultim pace growth market
remain somewhat uncertain
constraint regulatori issu reimburs hurdl
among clinic custom base meanwhil expect
continu headwind smaller microarray
segment
cannib result declin sequenc price
expect earn per share grow
compound annual assum earn grow
faster sale oper margin rise
compani repurchas share use
weight averag cost capit discount
give high uncertainti rate due
compani product concentr earli stage genom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
believ oper strong narrow moat
around genet analysi tool servic estim
oper share
sequenc market domin
high-throughput segment technolog help
scientist gener world sequenc data
purchas solexa genom reader instrument
earli sinc continu innov
significantli reduc cost sequenc therebi
enabl rapid expans sequenc applic
disrupt technolog remain high-risk concern
industri think firm
differenti technolog on-going innov larg
instal system base creat signific entri barrier
competitor therefor expect gener
econom profit current time capit
cost least next decad
sourc competit advantag appear
root intang asset switch cost
reli intang asset
issu pend patent unit state
earli keep competit bay applic
patent enjoy term keep competitor
directli copi technolog long period time
sinc even slightli differenti technic featur
caus end user prefer one tool similar tool
compani precis scientif end market intang
asset around technolog contribut
difficult firm engin given
complex field leav domin player
high-throughput applic
competit lower-throughput field thermo
think barrier entri high genom sequenc
sequenc market combin potenti
disrupt entrant highli technic field
bull-cas scenario valu per
share time expect earn scenario
assum revenu grow compound annual
next five year faster market adopt
genom sequenc less pressur compet
technolog less competit pressur think
oper margin rise earn per
share grow compound annual next
bear-cas scenario model slower penetr
genom sequenc technolog competit
emerg platform particularli lower-throughput
scenario revenu grow
compound annual next five year
oper margin declin slightli earn
per share grow period prop
share repurchas scenario result fair valu
approxim time expect earn
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
thank intersect three highli technic
instrument
complex data analysi expect ventur capit
continu flow earli stage market product
commerci prove extrem difficult
alway emerg small-scal method develop
major research univers manufactur scalabl
develop molecular enzym need process
amplifi genet materi microfluid engin
complex softwar algorithm assembl massiv
amount data support custom servic creat
sizabl hurdl sector focu earli stage
technolog ventur capit arm gener
acquisit prowess help give access new
technolog
gener differenti properti tool
affect cost accuraci speed variou test
enabl product featur creat intang asset
inform decis use tool specif
applic thank strong emphasi intern
innov includ spend nearli sale
research develop averag past five
year fund advanc boost featur throughput
flow cell densiti read length cycl time faster
camera chemistri process expect illumina
instrument continu lead industri sequenc
cost throughput accuraci forese futur
exampl human genom project took year
billion complet technolog
help reduc cost whole genom sequenc faster
moor law semiconductor
pace cost reduct innov unparallel
field creat signific entri barrier
potenti rival opinion firm rest
laurel either manag highlight
work path enabl genom
forese futur could expand
advantag applic genet test even
also benefit switch cost end user
wish use sequenc system dedic
reagent flow cell requir
compani sale dedic larg
instal base sequenc abl
count signific revenu stream relat
instrument like extend five year
long sequenc tool remain relev
abl count substanti consum revenu
use life instrument
life
relev sequenc technolog also
appear like continu rel long period
citat industri public workflow
develop around system need repeat
consist therefor think end user would need
signific reason jump ship tool
reproduc end user train perspect
switch cost pervas life scienc lab
may even becom import clinic lab
regul play role ensur test accuraci
workflow need standard less skill
threat product keep moat rate
narrow rather wide exampl nanopor technolog
spearhead oxford nanopor
technolog seen invest like
roch strato genia continu repres threat
current sequenc standard nanopor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
technolog could lower sequenc cost associ
sampl prepar amplif reagent also
enabl long read length fast run time much simpler
sequenc assembl data analysi far ont
devic minor competit threat
lower throughput product detect
accuraci appear issu ont technolog
lead rel high error rate also base
cursori analysi ont technolog think compani
repres greater threat long-read
technolog time could threaten core
busi eventu beyond nanopor technolog
sequenc techniqu could emerg eclips
technolog eventu well think
advantag like lead econom profit
least next year remain uncertain
advantag extend next year given
on-going disrupt technolog risk field
on-going threat disrupt technolog keep
moat rate narrow instead wide award
posit moat trend result strengthen
intang asset increas switch cost
continu innov recent introduct
low- mid- high-throughput applic
new product add firm intang asset
relat patent protect intellectu properti
differenti technolog unfortun transpar
perspect histori announc new
technolog readi market make
howev given consist spend close
sale expect continu improv
exist technolog stave competit enter new
applic introduc new sequenc approach
futur histori indic new launch
like focu reduc unit cost genom
sequenc expand possibl applic
technolog healthcar along compani
opportun also compani continu make select
acquisit expand
differenti technolog
although regulatori scrutini may rise wake
fail acquisit challeng
sever govern agenc around globe
mid-throughput categori
instal system base
system larg focus technolog
continu grow increas demand tool
new product launch high-throughput categori
introduc novaseq price
custom continu adopt platform
multi-year period instrument set alreadi
help reduc cost sequenc genom
previou standard expect
technolog enabl genom eventu
continu improv reagent technolog
continu improv upon nextseq platform price
use
clinic applic diagnost applic along
flexibl output option mid- high-throughput
platform instal base continu grow fast
pace recent announc new product launch earli
posit pull-through consum
recent risen compani previou target
system becom increasingli valuabl lab variou
applic low-throughput categori could
help smaller clinic diagnost lab extend
capabl sequenc current offer three
instrument iseq offer compact
sequenc solut low price
target gene small genom sequenc lab
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
increasingli use new instal system switch
cost associ workflow consist
reproduc concern continu rise along
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
market expand sequenc indic creat
larg growth opportun product
leapfrog platform lead market share
loss profit declin
larg grow instal base
signific on-going sale high-margin consum
instrument
oearli stage sequenc toolmak may seek sell
rather compet directli
genom behemoth may help keep
competit edg
oa signific portion growth requir
clinic adopt sequenc technolog
face challeng beyond competit relat
regul valid treatment guidelin
success depend manag abil
sustain innov astut capit alloc
guarante
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
given potenti disrupt technolog genom
end market end held
billion cash invest owe billion
convert debt princip time ebitda
significantli cash invest debt
remain confid abil meet oblig
debt convert equiti matur
million convert per share
million convert per share expect
compani cash flow gener remain robust rel
debt well million gener grow
billion base-cas scenario
rel small million avail decemb
excess cash may continu build balanc
sheet compani pay dividend
give high uncertainti rate
product concentr earli stage genom sequenc
market combin potenti disrupt entrant
highli technic field disrupt technolog
new genom sequenc platform greatest risk
view outpac current
sequenc competitor includ thermo fisher
pacif bioscienc ventur capit continu fund
could eventu
rapid pace innov consider
research develop shift toward technolog
could elimin need complic microfluid
prepar camera laser beyond potenti
read length suggest easier align sequenc
faster
use
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
less-compl data manag softwar
program awar multipl ventur develop
new sequenc technolog state advanc
difficult determin think technolog
earli phase develop suggest
near-term threat howev platform
nanopor shown promis earli publish
numer sequenc technolog fail
take flight includ method helico
point emerg technolog remain
larg untest
like face numer
develop challeng give
room run least intermedi term
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
capit group growth amer comp
capit research manag compani
share
fund
share
fund
assign exemplari stewardship rate
base compani histori shrewd capit alloc
help firm maintain return
doubl capit cost view innov
support high research develop
spend combin prescient well-tim
acquisit activ upheld impress
growth return
domin sequenc market larg stem
acquisit solexa gave
foundat
sequenc
machin persist leadership push
sequenc innov curv also build
sampl prepar data analysi posit
prefer sequenc platform
moleculo address platform
weak acquisit includ bluegnom
verinata health help lay groundwork
growth diagnost
manag face tall order quest sustain
blister pace
develop
field potenti disrupt
technolog one seriou misstep failur acquir
long-term success manag team
like cogniz threat anyon els
though think excel drive industri
innov pick winner capit deploy
jay flatley illumina ceo
transit role chairman like continu
consider
initi franci desouza succeed flatley ceo juli
join compani symantec
presid addit flatley chairmanship desouza
possess seat board director
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
john thompson -- board member sinc former
ceo symantec -- replac blain bowman lead
independ director follow retir
compens determin larg revenu
oper incom target perform stock unit
track earn per share benchmark three-year
period arent best measur valu creation
opinion that minor quibbl relat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
illumina beat revenu outlook pull
guidanc concern share fairli valu
result first quarter beat guidanc
due on-going crisi compani pull
outlook similar sever life science/
diagnost compani recent day plan give
detail late april report full result
point anticip chang fair valu
estim like delay rather cancel
demand share appear fairli valu
despit challeng late march gener
million sale first quarter high end
guidanc
rang million
manag note sale fell significantli end
march suspect weak relat
custom restrict access close facil outright
continu second quarter chang
work pattern client could hurt near-term
sale major revenu stream includ consum
sale instrument servic
sale
uncertainti around long mani custom
shutter oper pull guidanc
previous manag expect revenu growth
adjust ep growth base
disclosur suspect current estim
optimist may cut significantli
howev assum demand return
industry-lead sequenc tool crisi
abat think fair valu estim may remain roughli
also balanc sheet appear strong end
held billion cash
invest owe billion convert debt
princip time ebitda strong
financi posit remain confid abil
withstand on-going shock
turn fourth-quart oper result
guidanc roughli line expect
first glanc expect chang fair valu
system diagnost tool continu growth
instal system give us confid narrow moat
posit moat trend rate
quarter revenu grew year year
million roughli line consensu capiq
sequenc busi remain strong growth
quarter consumer-driven array busi
remain declin year year illumina
highlight place novaseq high throughput
nextseq medium throughput system record pace
earli compani also announc launch
nextseq sequenc system new
sequenc technolog becom standard care
cancer genet diseas patient next decad
scenario requir innov technolog enabl
sequenc lower price aim provid
solid top-lin trend signific cost control
abl boost adjust ep
growth versu weak compar period still higher
consensu pleas see illumina
gener strong free cash flow fourth quarter
help
expect slightli
exceed
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
domin market posit today effect
acquir commerci sequenc
technolog pressur rise manag produc
compel technolog intern invest earlier-stag
compani guarante succeed
interestingli day merger termin
key start-up oxford nanopor technolog announc
rais gbp million help fund
emerg next-gener sequenc threat
competitor make dent market share
econom profit current market leader may
despit perform guid roughli line
earn expect firm aim
revenu growth adjust ep
expect
near top-end guidanc overal
expect significantli chang
expect base trend outlook
regul rais signific concern
pend combin narrow-moat announc
merger agreement
termin plan acquisit slightli constrain
fair valu estim given rich valuat
offer therefor boost fair valu
estim per share
deal fall apart despit small termin fee
million pay
recent month merger face signific concern
global regul includ move block deal
feder trade commiss decemb
merg compani previous argu short-read
long-read pacif bioscienc genom
sequenc technolog differ enough clear
anti-trust concern announc though
firm accept defeat plan merger
regulatori concern domin
market may even open door new competit eventu
gener threat disrupt technolog new
competit forc remain key concern long-
term prospect concern keep moat rate
organ narrow rather wide despit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
